DocGo Inc. (DCGO) Free cash flow
- Free cash flow · 12 months (USD): Value $-25.83M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -8.77%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-25.83M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-22.71M − $3.12M ≈ $-25.83M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -8.77% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-25.83M ÷ $294.72M × 100 ≈ -8.77% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-22.71M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.11× | Operating cash flow / net income. Period ending 2026-06-30. $-22.71M ÷ $-206.39M ≈ 0.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -22.71M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 3.12M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -25.83M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 294.72M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -206.39M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-25.83M | (m) | $-22.71M | $3.12M | (m) | $294.72M | (m) | $-206.39M | (m) | (m) | -8.77% | 0.11× |
| 2026-03-31 | $16.63M | (m) | $20.58M | $3.94M | (m) | $301.71M | (m) | $-201.72M | (m) | (m) | 5.51% | -0.10× |
| 2025-12-31 | $29.91M | (m) | $34.45M | $4.54M | (m) | $322.20M | (m) | $-182.40M | (m) | (m) | 9.28% | -0.19× |
| 2025-09-30 | $53.87M | (m) | $57.86M | $3.99M | (m) | $368.09M | (m) | (m) | (m) | (m) | 14.63% | (m) |
| 2025-06-30 | $83.33M | (m) | $87.35M | $4.02M | (m) | $435.97M | (m) | (m) | (m) | (m) | 19.11% | (m) |
| 2025-03-31 | $86.28M | (m) | $90.63M | $4.35M | (m) | $520.50M | (m) | (m) | (m) | (m) | 16.58% | (m) |
| 2024-12-31 | $66.50M | (m) | $70.34M | $3.83M | (m) | $616.56M | (m) | (m) | (m) | (m) | 10.79% | (m) |
| 2024-09-30 | $45.37M | (m) | $51.53M | $6.16M | (m) | $694.97M | (m) | (m) | (m) | (m) | 6.53% | (m) |
| 2024-06-30 | $-31.56M | (m) | $-25.38M | $6.18M | (m) | $742.84M | (m) | (m) | (m) | (m) | -4.25% | (m) |
| 2024-03-31 | $-58.30M | (m) | $-51.74M | $6.56M | (m) | $703.37M | (m) | (m) | (m) | (m) | -8.29% | (m) |
| 2023-12-31 | $-71.81M | (m) | $-64.22M | $7.58M | (m) | $624.29M | (m) | (m) | (m) | (m) | -11.50% | (m) |
| 2023-09-30 | $-72.61M | (m) | $-67.04M | $5.56M | (m) | $533.83M | (m) | (m) | (m) | (m) | -13.60% | (m) |
| 2023-06-30 | $-19.56M | (m) | $-13.74M | $5.82M | (m) | $451.59M | (m) | (m) | (m) | (m) | -4.33% | (m) |
| 2023-03-31 | $-17.08M | (m) | $-12.51M | $4.57M | (m) | $435.63M | (m) | $20.49M | (m) | (m) | -3.92% | -0.61× |
| 2022-12-31 | $25.67M | (m) | $28.87M | $3.20M | (m) | $440.52M | (m) | $34.58M | (m) | (m) | 5.83% | 0.83× |
| 2022-09-30 | $24.83M | (m) | $28.81M | $3.98M | (m) | $453.05M | (m) | $43.87M | (m) | (m) | 5.48% | 0.66× |
| 2022-06-30 | $26.22M | (m) | $29.38M | $3.17M | (m) | $434.57M | (m) | $42.20M | (m) | (m) | 6.03% | 0.70× |
| 2022-03-31 | $13.05M | (m) | $17.70M | $4.65M | (m) | $386.92M | (m) | $30.55M | (m) | (m) | 3.37% | 0.58× |
| 2021-12-31 | $-6.76M | (m) | $-1.95M | $4.81M | (m) | $318.72M | (m) | $19.18M | (m) | (m) | -2.12% | -0.10× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |